Osaka, Japan

Ryo Iwamoto

USPTO Granted Patents = 4 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Suita, JP (2010 - 2012)
  • Osaka, JP (2012 - 2013)

Company Filing History:


Years Active: 2010-2013

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Ryo Iwamoto: Innovator in Monoclonal Antibody Development

Introduction

Ryo Iwamoto is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies. With a total of 4 patents to his name, Iwamoto's work is paving the way for advancements in medical treatments.

Latest Patents

Iwamoto's latest patents focus on a monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor (HB-EGF). These medicaments are designed to treat diseases related to the escalation of HB-EGF. The present invention provides a monoclonal antibody or an antibody fragment that binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF, and a secretory HB-EGF. This innovative approach addresses a critical need in the medical field.

Career Highlights

Ryo Iwamoto is currently associated with Kyowa Hakko Kirin Co., Limited, where he continues to push the boundaries of scientific research. His work has garnered attention for its potential impact on treating various diseases, showcasing his dedication to improving healthcare outcomes.

Collaborations

Iwamoto has collaborated with notable colleagues, including Eisuke Mekada and Shingo Miyamoto. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Ryo Iwamoto's contributions to the field of monoclonal antibodies highlight his role as an innovative inventor. His work not only addresses pressing medical needs but also exemplifies the importance of collaboration in scientific research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…